UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

The lancet oncology, 2021-06, Vol.22 (6), p.790-800

2021

Volltextzugriff (PDF)

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Clinical lymphoma, myeloma and leukemia, 2022-05, Vol.22 (5), p.e335-e339

2022

Volltextzugriff (PDF)

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

European journal of cancer (1990), 2016-02, Vol.54, p.11-17

2016

Volltextzugriff (PDF)

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Leukemia & lymphoma, 2019-09, Vol.60 (11), p.2705-2711

2019

Volltextzugriff (PDF)

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

European journal of haematology, 2021-02, Vol.106 (2), p.267-272

2021

Volltextzugriff (PDF)

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

The Lancet. Haematology, 2018-05, Vol.5 (5), p.e190-e200

2018

Volltextzugriff (PDF)

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial

Annals of hematology, 2020, Vol.99 (1), p.105-112

2020

Volltextzugriff (PDF)

Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?

The cancer journal (Sudbury, Mass.), 2012-09, Vol.18 (5), p.390-395

2012

Volltextzugriff (PDF)

18F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder

Leukemia & lymphoma, 2014-03, Vol.55 (3), p.515-519

2014

Volltextzugriff (PDF)

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report

EJHaem, 2021-11, Vol.2 (4), p.848-853

2021

Volltextzugriff (PDF)

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

Leukemia & lymphoma, 2012-12, Vol.53 (12), p.2397-2404

2012

Volltextzugriff (PDF)

Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy

Leukemia & lymphoma, 2012-10, Vol.53 (10), p.1949-1952

2012

Volltextzugriff (PDF)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

EJHaem, 2020-07, Vol.1 (1), p.133-141

2020

Volltextzugriff (PDF)

False-Positive 18F-FDG PET/CT Imaging: Dramatic "Flare Response" After Rituximab Administration

Clinical nuclear medicine, 2016-03, Vol.41 (3), p.e171-e172

2016

Volltextzugriff (PDF)

Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma

Clinical nuclear medicine, 2017-01, Vol.42 (1), p.e1-e7

2017

Volltextzugriff (PDF)

ABCL-396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial Program

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S397-S398

2021

Volltextzugriff (PDF)

Poster: ABCL-396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial Program

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S238-S238

2021

Volltextzugriff (PDF)

ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S394-S395

2021

Volltextzugriff (PDF)

Poster: ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S238-S238

2021

Volltextzugriff (PDF)

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

The Lancet (British edition), 2003-08, Vol.362 (9383), p.516-522

2003

Volltextzugriff (PDF)

Treatment for lymph node tuberculosis

BMJ, 2010-03, Vol.340 (mar10 3), p.c63-c63

2010

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(40)
Dissertationen
(1)

Sprache

Englisch
(41)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(17)
Female
(14)
Middle Aged
(13)
Adult
(12)
Aged
(12)
Male
(12)
Oncology
(10)
Hematology
(9)
Lymphoma
(9)
Aged, 80 And Over
(8)
Young Adult
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Adolescent
(5)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(5)
Treatment Outcome
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Biopsy
(4)
Chemotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial

Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?

18F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

False-Positive 18F-FDG PET/CT Imaging: Dramatic "Flare Response" After Rituximab Administration

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma

ABCL-396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial Program

Poster: ABCL-396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial Program

ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

Poster: ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

Treatment for lymph node tuberculosis

Aktive Filter

Suchergebnisse filtern